143.37 USD
-0.32 (-0.22%)
142.5 USD
-0.87 (-0.61%)
Taking everything into account, TMDX scores 6 out of 10 in our fundamental rating. TMDX was compared to 185 industry peers in the Health Care Equipment & Supplies industry. While TMDX has a great health rating, its profitability is only average at the moment. TMDX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make TMDX a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
- TMDX had positive earnings in the past year.
- In the past year TMDX had a positive cash flow from operations.
- TMDX had negative earnings in 4 of the past 5 years.
- TMDX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- TMDX has a Return On Assets of 9.70%. This is amongst the best in the industry. TMDX outperforms 93.51% of its industry peers.
- With an excellent Return On Equity value of 25.84%, TMDX belongs to the best of the industry, outperforming 96.76% of the companies in the same industry.
- TMDX has a Return On Invested Capital of 8.75%. This is amongst the best in the industry. TMDX outperforms 88.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| ROIC | 8.75% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 16.20%, TMDX belongs to the best of the industry, outperforming 92.97% of the companies in the same industry.
- TMDX's Operating Margin of 16.94% is amongst the best of the industry. TMDX outperforms 87.57% of its industry peers.
- With a decent Gross Margin value of 60.28%, TMDX is doing good in the industry, outperforming 61.62% of the companies in the same industry.
- TMDX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TMDX is destroying value.
- TMDX has more shares outstanding than it did 1 year ago.
- TMDX has more shares outstanding than it did 5 years ago.
- TMDX has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 6.03 indicates that TMDX is not in any danger for bankruptcy at the moment.
- TMDX has a better Altman-Z score (6.03) than 80.00% of its industry peers.
- TMDX has a debt to FCF ratio of 4.24. This is a neutral value as TMDX would need 4.24 years to pay back of all of its debts.
- TMDX has a better Debt to FCF ratio (4.24) than 80.54% of its industry peers.
- A Debt/Equity ratio of 1.43 is on the high side and indicates that TMDX has dependencies on debt financing.
- TMDX's Debt to Equity ratio of 1.43 is on the low side compared to the rest of the industry. TMDX is outperformed by 78.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Altman-Z | 6.03 |
ROIC/WACC0.91
WACC9.65%
2.3 Liquidity
- TMDX has a Current Ratio of 7.69. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of TMDX (7.69) is better than 88.11% of its industry peers.
- TMDX has a Quick Ratio of 7.13. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Quick ratio value of 7.13, TMDX belongs to the best of the industry, outperforming 88.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 |
3. Growth
3.1 Past
- TMDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 162.77%, which is quite impressive.
- The Revenue has grown by 41.20% in the past year. This is a very strong growth!
- The Revenue has been growing by 79.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
3.2 Future
- TMDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.25% yearly.
- TMDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.23% yearly.
EPS Next Y163.67%
EPS Next 2Y71.04%
EPS Next 3Y53.35%
EPS Next 5Y33.25%
Revenue Next Year39.67%
Revenue Next 2Y29.73%
Revenue Next 3Y25.56%
Revenue Next 5Y21.23%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 58.04, TMDX can be considered very expensive at the moment.
- TMDX's Price/Earnings ratio is a bit cheaper when compared to the industry. TMDX is cheaper than 68.11% of the companies in the same industry.
- TMDX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.47.
- TMDX is valuated quite expensively with a Price/Forward Earnings ratio of 48.52.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 69.19% of the companies listed in the same industry.
- TMDX is valuated expensively when we compare the Price/Forward Earnings ratio to 24.26, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 58.04 | ||
| Fwd PE | 48.52 |
4.2 Price Multiples
- 67.57% of the companies in the same industry are more expensive than TMDX, based on the Enterprise Value to EBITDA ratio.
- 75.68% of the companies in the same industry are more expensive than TMDX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 40.62 | ||
| EV/EBITDA | 40.73 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as TMDX's earnings are expected to grow with 53.35% in the coming years.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y71.04%
EPS Next 3Y53.35%
5. Dividend
5.1 Amount
- TMDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
143.37
-0.32 (-0.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-29 2025-10-29/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners111.19%
Inst Owner Change0.01%
Ins Owners2.95%
Ins Owner Change-0.16%
Market Cap4.90B
Revenue(TTM)566.35M
Net Income(TTM)91.77M
Analysts83
Price Target148.84 (3.82%)
Short Float %21.09%
Short Ratio7.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)1.04%
PT rev (3m)-0.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.51%
EPS NY rev (1m)0%
EPS NY rev (3m)10.25%
Revenue NQ rev (1m)-0.12%
Revenue NQ rev (3m)0.3%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 58.04 | ||
| Fwd PE | 48.52 | ||
| P/S | 8.65 | ||
| P/FCF | 40.62 | ||
| P/OCF | 27.47 | ||
| P/B | 13.79 | ||
| P/tB | 14.34 | ||
| EV/EBITDA | 40.73 |
EPS(TTM)2.47
EY1.72%
EPS(NY)2.95
Fwd EY2.06%
FCF(TTM)3.53
FCFY2.46%
OCF(TTM)5.22
OCFY3.64%
SpS16.57
BVpS10.4
TBVpS10
PEG (NY)0.35
PEG (5Y)N/A
Graham Number24.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| ROCE | 11.08% | ||
| ROIC | 8.75% | ||
| ROICexc | 18.94% | ||
| ROICexgc | 19.61% | ||
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% | ||
| FCFM | 21.29% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Debt/EBITDA | 4.16 | ||
| Cap/Depr | 224.51% | ||
| Cap/Sales | 10.19% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 146.57% | ||
| Profit Quality | 131.41% | ||
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 | ||
| Altman-Z | 6.03 |
F-Score7
WACC9.65%
ROIC/WACC0.91
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y163.67%
EPS Next 2Y71.04%
EPS Next 3Y53.35%
EPS Next 5Y33.25%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
Revenue Next Year39.67%
Revenue Next 2Y29.73%
Revenue Next 3Y25.56%
Revenue Next 5Y21.23%
EBIT growth 1Y205.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year317.92%
EBIT Next 3Y87.46%
EBIT Next 5Y68.49%
FCF growth 1Y187.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y802.91%
OCF growth 3YN/A
OCF growth 5YN/A
TRANSMEDICS GROUP INC / TMDX FAQ
Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to TMDX.
Can you provide the valuation status for TRANSMEDICS GROUP INC?
ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.
How profitable is TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.
How financially healthy is TRANSMEDICS GROUP INC?
The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 7 / 10.